Skip to main content
Login
Contact
Subscribe
Search form
Search
The Punxsutawney Spirit
Home
Forms
Delivery Concerns
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Local Guide
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Astrazeneca Plc
(NY:
AZN
)
47.62
USD
-0.58 (-1.20%)
Official Closing Price
/ Updated:
6:30 PM EST, Dec 5, 2019
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
2,302,400
Open
48.07
Bid (Size)
45.00 (1)
Ask (Size)
59.92 (1)
Prev. Close
48.20
Today's Range
47.51 - 48.09
52wk Range
35.30 - 49.22
Shares Outstanding
2,533,294,824
Dividend Yield
2.88%
Performance
YTD
+25.98%
+25.98%
1 Month
+0.89%
+0.89%
3 Month
+6.39%
+6.39%
6 Month
+22.64%
+22.64%
1 Year
+22.51%
+22.51%
Top News
More News
Advanced Medical Technologies Help Stem the Evergrowing Spread of Ailments
November 26, 2019
FinancialBuzz.com News Commentary
Read More
from
PR Newswire
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
Today 6:38 EST
AstraZeneca and Merck/MSD were approved to sell their jointly marketed PARP inhibitor in China as a first-line maintenance treatment for BRCA-mutated ovarian cancer. In a Phase III trial among patients...
Read More
from
ChinaBio® Today
More News
Read More
REFILE-AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
Today 3:23 EST
category
companyNews
from
Reuters: Company News
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
Today 6:38 EST
from
ChinaBio® Today
AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
Today 2:11 EST
category
companyNews
from
Reuters: Company News
China to use drug bulk-buy program to close price gap
November 30, 2019
category
companyNews
from
Reuters: Company News
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street
November 29, 2019
category
TECD
,
Futures
,
Benzinga
, and 11 more.
from
Benzinga
Is Clovis Oncology Really a Buyout Candidate?
December 03, 2019
category
Market News
,
JNJ
,
CLVS
, and 3 more.
from
Motley Fool
China Adds 70 Drugs to Insurance Reimbursement List; Negotiates 61% Average Price Cuts
December 02, 2019
from
ChinaBio® Today
UPDATE 1-AstraZeneca's Imfinzi gets speedy FDA review for small cell lung cancer
November 29, 2019
category
companyNews
from
Reuters: Company News
Here's Why Lexicon Pharmaceuticals Is Tumbling Today
December 02, 2019
category
LXRX
,
MRK
,
AZN
, and 5 more.
from
Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.